Search

Displaying results 931 - 940 of 7062 in total
  1. Drug

    Aducanumab

    go.drugbank.com/drugs/DB12274
    ApprovedInvestigational

    [A235720] Development of aducanumab was discontinued in March 2019 when two phase 3 clinical trials did not pass futility analysis; however, Biogen sought FDA approval in October 2019 after reanalyzing … [A235668,A235730] Aducanumab is a recombinant antibody derived from patients with slow or absent cognitive decline, and phase 1b clinical trial data have shown patients treated with aducanumab show a reduction

  2. Drug

    LErafAON

    go.drugbank.com/drugs/DB04973
    Investigational

    Phase I/II trials commenced in March 2001 and were ongoing as of June 2003.

  3. Drug

    Radium Ra 223 dichloride

    go.drugbank.com/drugs/DB08913
    ApprovedInvestigational

    The FDA label includes a warning that Radium Ra 223 Dichloride should not be used in women who are pregnant or may become pregnant due to the high risk of fetal harm. … Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles.

    Synonyms: Radium chloride Ra-223, Radium (Ra-223) dichlorideProducts: Radium Ra 223 Dichloride
  4. Drug

    Dalbavancin

    go.drugbank.com/drugs/DB06219
    ApprovedInvestigational

    Dalbavancin acts by interfering with bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of nascent cell wall peptidoglycan and preventing cross-linking [FDA Label, F2356, A4072 … Modifications from these older glycoprotein classes facilitated a similar mechanism of action for dalbavancin but with increased activity and once-weekly dosing [FDA Label, F2356, A4072, A4073].

  5. Drug

    Thonzylamine

    go.drugbank.com/drugs/DB11235
    Approved

    Thonzylamine is an antihistamine and anticholinergic drug. It is available as combination products with DB04837 or DB00388 for temporary relief of symptoms of common cold, hay fever (allergic rhinitis) or other upper respiratory allergies.

    Mixtures: Poly-Hist DM
  6. Drug

    Vilazodone

    go.drugbank.com/drugs/DB06684
    ApprovedInvestigational

    Vilazodone is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT(1A) receptors[Label,A177622]. … Vilazodone was given FDA approval on January 21, 2011[L6046,A177622].

  7. Drug

    Zavegepant

    go.drugbank.com/drugs/DB15688
    ApprovedInvestigational

    [A258190,A258195] In March 2023, the FDA approved the use of zavegepant nasal spray for the acute treatment of migraine with or without aura in adults. … Zavegepant (BHV-3500) is a calcitonin gene-related peptide (CGRP) receptor antagonist.

  8. Drug

    Ozenoxacin

    go.drugbank.com/drugs/DB12924
    Approved

    As of December 11, 2017 the FDA approved Ferrer Internacional S.A.' … Despite being a common and highly contagious bacerial skin infection that affects millions of children and adults in the United States each year, ozenoxacin cream is a novel, non-fluorinated quinolone

  9. Drug

    Obiltoxaximab

    go.drugbank.com/drugs/DB05336
    Approved

    Obiltoxaximab is a chimeric IgG1 kappa monoclonal antibody (mAb) that binds the PA component of B. anthracis toxin. It has an approximate molecular weight of 148 kDa.

  10. Drug

    Naloxone

    go.drugbank.com/drugs/DB01183
    ApprovedInvestigationalVet approved

    [L33734] Kits commonly include the supplies necessary to treat an overdose in a non-medical setting such as alcohol swabs, syringes, a rescue breathing mask, and instructions for use. … [L33714,L33719] Naloxone was granted FDA approval on 13 April 1971.[L33709]

    Mixtures: TILIDIN HEXAL COMP D-PUMPE, TARGIN ® 20 MG / 10 MG TABLETAS DE LIBERACIÓN PROLONGADAProducts: NALOKSON HIDROKLORUR ENJ.10AMP(D)(E